Abstract

miR-125b is frequently dysregulated in different diseases. Activation of hepatic stellate cells (HSCs) is a critical event during liver fibrogenesis. However, the function and its underlying mechanism of miR-125b in HSC activation and liver fibrosis are still unknown. Here, we showed that miR-125b was upregulated in HSCs, but not in hepatocytes, during hepatic fibrogenesis in vivo and upon culture activation in vitro. Inhibition of miR-125b suppressed the expression of profibrogenic genes in culture-activated primary HSCs and reduced the basal and transforming growth factor β (TGF-β)-induced alpha-smooth muscle actin (α-SMA) expression and cell contraction of the immortalized HSC cell line. In contrast, ectopic expression of miR-125b promoted α-SMA expression and HSC contraction. Moreover, antagonizing miR-125b in vivo significantly alleviated liver fibrosis in CCl4-treated mice. Mechanistically, overexpression of miR-125b in HSCs enhanced RhoA activity by directly targeting StAR-related lipid transfer (START) domain containing 13 (Stard13), a RhoA-specific GTPase-activating protein, whereas knockdown of miR-125b abrogated RhoA activation. Furthermore, inhibition of RhoA or its downstream molecules, Mrtf-A and Srf, attenuated the miR-125b-induced α-SMA expression and HSC contraction. Therefore, our findings identify a miR-125b-Stard13-RhoA-α-SMA signaling cascade in HSCs and highlight its importance in hepatic fibrosis.

Highlights

  • Hepatic fibrosis is the outcome of chronic liver injury in response to various etiologies

  • This study reveals a promotive function of miR-125b in hepatic stellate cells (HSCs) activation and hepatic fibrosis, and this may be beneficial for developing miR-125b-based therapy for liver fibrosis

  • MiR-125b Is Upregulated in Activated HSCs, and Inhibition of miR-125b Attenuates Hepatic Fibrosis In Vivo To assess the function of miR-125b in liver fibrosis, we first evaluated by qRT-PCR the expression of miR-125b in fibrotic liver tissues

Read more

Summary

Introduction

Hepatic fibrosis is the outcome of chronic liver injury in response to various etiologies. It is characterized by excess accumulation of abnormal extracellular matrix (ECM) and disruption of hepatic architecture.[1,2] During liver fibrosis, ECM is converted from a collagen IV/VI-rich matrix to a collagen I/III-rich one, resulting in liver stiffness and distortion of the sinusoidal architecture. Long-term fibrosis leads to cirrhosis and subsequent liver dysfunction and hepatocellular carcinoma (HCC).[3] Activation of hepatic stellate cells (HSCs) plays a critical role in liver fibrosis and is characterized by the conversion from vitamin A-storing cell into myofibroblast that expresses excess profibrogenic genes, such as alpha-smooth muscle actin (a-SMA), collagen type I alpha 1 chain (Col1a1), collagen type I alpha 2 chain (Col1a2), tissue inhibitor of metalloproteinase 1 (Timp1), and fibronectin 1 (Fn1). Whether microRNAs (miRNAs) have a role in these processes remains poorly understood

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call